Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma

• Published in: Zhongliu fangzhi yanjiu Vol. 42; no. 2; pp. 185 - 189
• Main Authors: LI, Zihuang, LI, Xianming, YANG, Dong, XU, Gang, ZHOU, Yayan, WU, Shihai, LI, Zhuangling
• Format: Journal Article
• Language: Chinese
• Published: 01.01.2015
• ISSN: 1000-8578
• DOI: 10.3971/j.issn.1000-8578.2015.02.019

Objective To observe the efficacy and safety of temozolomide(TMZ) combined with radiotherapy on patients with high-grade glioma(HGG), and to explore the prognostic factors for HGG patients. Methods We retrospectively analyzed the clinical data of 50 patients with newly diagnosed HGG treated with TMZ combined with radiotherapy. All patients were treated with three-dimensional conformal technique(3DCRT) or intensity-modulated radiotherapy(IMRT), and received oral TMZ[75 mg/(m super(2) times d)] during radiotherapy; the adjuvant chemotherapy scheme TMZ[(150-200) mg/(m super(2) times d)] for 5 days, 28 days as a cycle, was used after radiochemotherapy. We analyzed the clinical outcome and safety of those HGG patients. Multivariate analysis was used to analyze some factors related to prognostic significance, including gender, age, Karnovsky performance scores(KPS), excision degree, pathological grade, interval time between surgery and radiochemotherapy, radiotherapy techniques and adjuvant TMZ cycle number. Result